Immunicum AB (STO:IMMU), a biopharmaceutical company developing therapeutic cancer vaccines, reported on Thursday a change in the number of shares and votes in the company, as a result of the implementation of a share issue with preferential rights for the company's existing shareholders.
Under this rights issue, the number of shares and votes have increased by 20,383,412, which has increased the company's share capital by SEK 1,019,170.60.
As of 31 January 2019, the total share capital in Immunicum amounts to SEK4,612,876.55 and the total number of shares and votes amount to 92,257,531.
(EUR1.00=SEK10.36)
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100